Status:
COMPLETED
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
Lead Sponsor:
Eudocia Quant Lee, MD
Collaborating Sponsors:
Dartmouth-Hitchcock Medical Center
University of California, San Diego
Conditions:
Malignant Glioma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine if armodafinil is safe and effective in treating fatigue in patients with malignant gliomas undergoing treatment with radiotherapy plus temodar. Armo...
Detailed Description
* Since no one knows for certain if armodafinil improves fatigue in brain tumor patients undergoing radiation therapy, participants will be randomized into one of two study groups. Half of the partici...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Histologically confirmed malignant glioma including anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma (WHO grade III/IV), glioblastoma multiforme (WHO grade IV) or gliosarcoma. Patients with a grade II astrocytoma, mixed oligo-astrocytoma or oligodendroglioma who are being treated with irradiation are also eligible
- Scheduled to receive irradiation to a total dose of 50-60 Gy. Patients receiving hyperfractionated radiotherapy are also eligible
- KPS of 70% or greater
- Electrolytes within normal institutional limits: BUN and Creatinine \< 2.5 x ULN: AST, ALT, Bilirubin \< 2.5 x ULN
- Able to swallow medication
Exclusion
- History of recent cardiac arrhythmia or unstable angina
- Has taken a psychostimulant or a monoamine oxidase inhibitor on a regular basis within the past 30 days
- Clinically significant untreated sleep apnea
- A history of clinically significant cardiac disease, including a history of recent myocardial infarction, history of unstable angina, history of left ventricular hypertrophy, or a history of ischemic ECG changes, chest pain, arrhythmia, or other clinically significant manifestations of mitral valve prolapse in association with use of CNS stimulants (e.g. caffeine, amphetamines, methylphenidate)
- Uncontrolled hypertension, alcohol or drug abuse, severe headaches, glaucoma, narcolepsy, clinically significant untreated sleep apnea, psychotic disorder or Tourette's syndrome
- Patients taking warfarin for anticoagulation are eligible, but monitoring of prothrombin times is suggested as a precaution
- Hemoglobin level of less then 11 g/dl
- Laboratory evidence of hypothyroidism with an elevated TSH concentration in the blood greater than 5.0 mlU/L
- Current treatment or history of psychotic disorder, bipolar disorder, or anxiety disorder
- Patients with a score of \> 28 on the Beck depression inventory consistent with severe depression
- Known hypersensitivity to armodafinil or related compounds
- Patients who have been receiving MAO inhibitors during the past 14 days
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00766467
Start Date
September 1 2008
End Date
July 1 2014
Last Update
July 28 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD San Diego
La Jolla, California, United States
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
3
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
4
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03766